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Abstract
Men who have sex with men (MSM) are at high risk for disease associated with human 
papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 
and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance 
System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis 
to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Among 3221 
MSM aged 18–26, 157 (4.9%) reported ≥1 vaccine dose. Uptake was higher among men who 
visited a healthcare provider (aPR 2.3, CI: 1.2–4.2), disclosed same-sex sexual attraction/behavior 
to a provider (aPR 2.1, CI: 1.3–3.3), reported a positive HIV test (aPR 2.2, CI: 1.5–3.2), or 
received hepatitis vaccine (aPR 3.9, CI: 2.4–6.4). Of 3064 unvaccinated MSM, 2326 (75.9%) had 
visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among 
MSM provide a baseline as vaccination recommendations are implemented.
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1. Introduction
Men who have sex with men (MSM) are at high risk for infection and disease associated 
with human papillomavirus (HPV). A meta-analysis of 53 studies found the pooled 
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prevalence of any anal HPV was 92.6% among HIV-infected MSM and 63.9% among HIV-
uninfected MSM [1]. Among MSM visiting U.S. sexually transmitted disease (STD) clinics, 
the prevalence of genital warts was 7.5% [2]. In a study involving 34,189 HIV-infected and 
114,260 HIV-uninfected individuals, anal cancer incidence per 100,000 person-years was 
131 among MSM, 46 among HIV-infected men, and 2 among other HIV-uninfected men 
[3]. Quadrivalent HPV vaccine clinical trials in MSM demonstrated high efficacy for 
prevention of anal cancer precursor lesions and genital warts [4].
In the United States, quadrivalent HPV vaccine was first licensed for use in females in 2006 
and then for use in males in 2009 [5]. At that time in 2009, the Advisory Committee on 
Immunization Practices (ACIP) issued national policy stating that males may be vaccinated. 
In late 2011, ACIP added HPV vaccine to the routine immunization schedule for U.S. males, 
recommending that it be given to all boys at age 11 or 12 years and through age 21 years if 
not previously vaccinated [5]. HPV vaccine is also recommended through age 26 years for 
all MSM and immunocompromised individuals if not previously vaccinated [5,6]. ACIP 
recommendations are followed by health care providers and also have impact on vaccine 
availability through federal programs and private health insurance in the United States [6,7].
Data on HPV vaccine uptake among MSM are scarce. Results from the 2008 National HIV 
Behavioral Surveillance System (NHBS) suggested that there would be many opportunities 
for young MSM to receive recommended care including HPV vaccine, as 88.9% of 
participants had accessed health care within the previous 12 months and 61.3% had 
disclosed same-sex sexual attraction/behavior to a healthcare provider [8]. Using data from 
the 2011 NHBS – collected after quadrivalent vaccine was licensed, but largely before it was 
routinely recommended by ACIP for males in the United States – we aimed to assess 
baseline HPV vaccine uptake among U.S. MSM through age 26 years.
2. Materials and methods
NHBS monitors HIV-associated behaviors and HIV prevalence in the 20 U.S. cities with the 
largest AIDS burden. Detailed methods have been reported elsewhere [9,10]. Cross-
sectional data reported in this analysis are from MSM enrolled in 2011 for interviews and 
HIV testing. Participant enrollment occurred using venue-based, time-space sampling at 
locations where MSM congregate, such as bars, clubs, and social organizations. For 
consenting participants aged ≥18 years residing in the metropolitan statistical area and who 
had not participated previously in NHBS during the current survey cycle, trained 
interviewers used handheld computers to administer, in English or Spanish, a standardized, 
anonymous questionnaire about demographics, sexual behavior, HPV vaccination history, 
HIV/STD testing, and other health care use. Interview participants received a cash or gift 
card incentive typically worth $25 [9–11]. Activities for NHBS were approved by local 
institutional review boards (IRB) for each of the 20 participating cities. NHBS activities 
were determined to be research in which the Centers for Disease Control and Prevention 
(CDC) were not directly engaged and, therefore, did not require separate review by CDC 
IRB.
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Eligible participants were born male and reported ever having a male sex partner. After 
describing the percentage of all MSM reporting HPV vaccine by age, we limited further 
analyses to MSM aged 18–26 years.
Statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, 
NC). We calculated descriptive frequencies and performed bivariate analyses using Pearson 
chi-square tests to assess associations between self-reported receipt of HPV vaccine and 
demographic characteristics, behavioral risk factors, and other sexual health care. In 
addition, among MSM who reported not receiving HPV vaccine, we assessed recent health 
care visits. To identify factors associated with HPV vaccine uptake, we estimated prevalence 
ratios and 95% confidence intervals (CIs) using multivariate analysis and Poisson regression 
modeling with robust standard errors. To select variables for this model, we first screened 
out variables that were not significant on bivariate analysis at alpha = 0.05 [8]. To avoid 
collinearity in measures of health care access, we selected one variable to include in the 
model (health care visits in the past 12 months) and did not include other related variables 
that were also significant on bivariate analysis (STD and HIV testing and diagnoses in the 
past 12 months).
3. Results
Of 9828 MSM aged ≥18 years who consented to the 2011 NHBS survey, 9819 with valid 
data were included in the analyses [11]. Of these, 262 (2.7%) reported having received ≥1 
dose of HPV vaccine (Table 1). Most men who reported receipt of HPV vaccine were aged 
≤26 years, within the recommended age range for vaccination. Among men older than 26 
years who reported HPV vaccine receipt, HIV infection was common: 25 (71.4%) of 35 
vaccinated men aged >40 years were HIV-infected, compared with 15 (38.5%) of 39 
vaccinated men aged 31–40 years and 35 (18.6%) of 188 men aged ≤30 years.
Among 3221 MSM aged 18–26 years, 157 (4.9%) reported having received ≥1 dose of HPV 
vaccine. Of these, 44 (28.0%) reported vaccine receipt during 2006–2009, 96 (61.1%) 
during 2010–2011, and 17 (10.8%) were unsure of the timing.
In bivariate analysis among men aged 18–26 years, HPV vaccine uptake was not 
significantly associated with any demographic factors (Table 2). Vaccine uptake was 
significantly higher among men who reported having access to care and receiving other 
sexual health care, including those who had any health insurance (5.6%), had visited a 
healthcare provider in the past year (5.9%), had disclosed male–male sexual attraction/
behavior to a health-care provider (6.3%), had been vaccinated against hepatitis (7.4%), or 
had been tested for HIV (5.8%) or another STD (7.8%) in the past year. Vaccine uptake was 
also significantly higher among men who had received a diagnosis of chlamydia, gonorrhea, 
or syphilis within the past 12 months (8.1%); who had ever received a diagnosis of genital 
warts (10.3%), or who reported having had a positive HIV test (13.4%). Finally, vaccine 
uptake was significantly higher among those reporting greater numbers of sex partners in the 
past 12 months.
In the multivariate model, four factors predicted HPV vaccine uptake: visiting a health care 
provider within the past year (aPR 2.3, CI: 1.2–4.2); ever disclosing male–male sexual 
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attraction/behavior to a health care provider (aPR 2.1, CI: 1.3–3.3); reporting a positive test 
for HIV infection (aPR 2.2, CI: 1.5–3.2); and reporting any hepatitis vaccination (aPR 2.2, 
CI: 1.5–3.2) (Table 2).
Of 3064 MSM aged 18–26 years in the target age range for HPV vaccine who reported 
being unvaccinated, 2326 (75.9%) had visited a health care provider within the past year.
4. Discussion
These are the first national data on HPV vaccine coverage among MSM in the United States. 
At 4.9%, coverage among MSM aged 18–26 years was low before HPV vaccine was 
routinely recommended for males in late 2011. Data on HPV vaccine uptake among U.S. 
MSM in 2011 can be used as a baseline to evaluate progress as vaccine recommendations 
are implemented.
Several factors predicted HPV vaccine uptake among MSM, including having received a 
hepatitis vaccine and having visited a health care provider in the past year. An additional 
predictor was disclosure of same-sex sexual attraction/behavior to a healthcare provider, an 
important precursor to receiving care recommended specifically for MSM, particularly those 
aged 22–26 years for whom HPV vaccination is recommended [5,12]. HIV-infected MSM 
have two indications for receiving HPV vaccine and, therefore, the higher uptake among this 
group is encouraging; accumulating data show that HPV vaccine has good immunogenicity 
in this group [13,14].
In the United States, data on HPV vaccine coverage in adolescents are provided by the 
National Immunization Survey-Teen; in 2011, an estimated 8.3% of boys aged 13–17 years 
received ≥1 dose of HPV vaccine [15]. This increased to 20.8% in 2012 [16]. Ideally, over 
time, more MSM will receive HPV vaccine before onset of sexual activity [17]. In the 
meantime, the fact that three-quarters of unvaccinated MSM had visited a health care 
provider within the past 12 months suggests that health care settings offer opportunities for 
HPV vaccination in this age group.
This analysis is subject to several limitations. Vaccine status is self-reported and may be 
subject to recall bias. Furthermore, the number of doses of HPV vaccine was not assessed in 
NHBS and thus vaccine series completion could not be evaluated. In addition, venue-based 
sampling does not represent all MSM, particularly those who live in rural areas, who do not 
disclose male–male sexual behavior, or who may not frequent venues where MSM 
congregate.
Improving HPV vaccine uptake in this population could be facilitated by MSM having 
access to a healthcare provider who provides vaccine, being willing to disclose same-sex 
sexual attraction/behavior, and accepting recommended vaccinations. Most MSM in this 
analysis, including three out of four unvaccinated MSM, had visited a health care provider 
recently, and two out of three had disclosed. A systematic review revealed that although 
HPV knowledge was generally poor among MSM, most had positive attitudes about the 
vaccine and, in two studies, believed it would be “good, safe, smart, easy, important, and 
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harmless” [18–20]. Vaccinations recommended by ACIP generally are covered by health 
insurance.
5. Conclusion
All young MSM should have the opportunity to receive HPV vaccine. Although ideally it 
should be administered before onset of sexual activity, quadrivalent HPV vaccine is 
recommended for U.S. MSM through age 26 years. Health care settings offer opportunities 
to increase coverage in this population.
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Table 1
Men who have sex with men reporting ≥1 dose of HPV vaccine, by self-reported HIV status and age – 
National HIV Behavioral Surveillance System, United States, 2011.
Age (years) All participants
N
Received ≥1 dose of HPV 
vaccine, among all 
participants
n (%)
Self-reported positive HIV 
test, among all participants
n (%)
Received ≥1 dose of HPV vaccine, 
among participants reporting a 
positive HIV test
n (%)
Total 9819 262 (2.7) 1333 (13.6) 75 (5.6)
18–26 3221 157 (4.9) 224 (6.9) 30 (13.4)
27–30 1334 31 (2.3) 145 (10.9) 5 (3.4)
31–40 2225 39 (1.8) 331 (14.9) 15 (4.5)
>40 3039 35 (1.2) 633 (20.8) 25 (3.9)
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Table 2
Predictors of self-reported receipt of HPV vaccine among young men aged 18–26 years who have sex with 
men — National HIV Behavioral Surveillance System, United States, 2011.
Characteristic Participants
N




Adjusted prevalence ratio (95% CI)
Total 3221 157 (4.9)
Age (years) 0.40
 18–21 1094 56 (5.1)
 22–26 2127 101 (4.7)
Race 0.27
 Black or African American 1155 59 (5.1)
 White 816 36 (4.4)
 Multiracial 125 12 (9.6)
 Hispanic or Latino 978 48 (4.9)
 Otherb 140 2 (1.4)
Education completed 0.50
 Less than high school 228 8 (3.5)
 High school diploma 1117 48 (4.3)
 Some college or higher 1876 101 (5.4)
Sexual identity 0.79
 Heterosexual or straight 55 0 (0)
 Homosexual or gay 2537 127 (5.0)
 Bisexual 618 30 (4.8)
Census region 0.21
 South 1192 52 (4.4)
 Northeast 775 37 (4.8)
 Midwest 436 26 (6.0)
 West 675 39 (5.8)
 Territory (San Juan, PR) 143 3 (2.1)
Health insurance 0.03
 None 1186 46 (3.9) Ref
 Any 2015 111 (5.5) 1.1 (0.8–1.6)
Usual place of care 0.06
 None 556 20 (3.6)
 One 2367 128 (5.4)
 More than one 274 8 (2.9)
Usual place of care typec 0.07
 Clinic or health center 810 50 (6.2)
 Doctor’s office or HMO 1257 72 (5.7)
 Hospital emergency room 488 12 (2.5)
 Some other place 76 2 (2.6)
Visited a health care provider within 12 months <0.01













Meites et al. Page 9
Characteristic Participants
N




Adjusted prevalence ratio (95% CI)
 No 749 12 (1.6) Ref
 Yes 2471 145 (5.9) 2.3 (1.2–4.2)
Disclosed same-sex sexual attraction/behavior to a health care provider <0.01
 No 1075 22 (2.0) Ref
 Yes 2143 135 (6.3) 2.1 (1.3–3.3)
Tested for HIV within 12 months 0.01
 No 991 27 (2.7)
 Yes 2226 130 (5.8)
Tested for an STD within 12 monthsd <0.01
 No 1680 38 (2.3)
 Yes 1536 119 (7.7)
HIV test result (self-reported) <0.01
 Negative 2537 116 (4.6) Ref
 Positive 224 30 (13.4) 2.2 (1.5–3.2)
 Unknown 460 11 (2.4) 0.9 (0.5–1.7)
Diagnosed with herpes ever 0.50
 No 3137 149 (4.7)
 Yes 81 8 (9.9)
Diagnosed with genital warts ever 0.05
 No 3109 145 (4.7)
 Yes 107 11 (10.3)
Diagnosed with an STD within 12 monthsd 0.04
 No 2837 126 (4.4)
 Yes 383 31 (8.1)
Vaccinated against hepatitis ever <0.01
 No 1208 18 (1.5) Ref
 Yes 1822 132 (7.2) 3.9 (2.4–6.4)
Number of sex partners within 12 months <0.01
 0–1 577 23 (4.0) Ref
 2–3 1031 42 (4.1) 1.0 (0.6–1.7)
 4–5 597 28 (4.7) 1.1 (0.7–1.9)
 >5 1016 64 (6.3) 1.5 (0.9–2.3)
a
Numbers may not add to total due to missing data.
b
Includes Asian, Pacific Islander, American Indian, multiple races, and other race.
c
Among participants reporting ≥1 usual place of care.
d
Chlamydia, gonorrhea, or syphilis.
Vaccine. Author manuscript; available in PMC 2015 December 14.
